Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Rule

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
British Journal of Haematology|December 4, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysisJennifer R Brown, Javid Moslehi, Michael S Ewer, et al.
The Lancet. Haematology|December 24, 2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyRoger G Owen, Helen McCarthy, Simon Rule, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
British Journal of Haematology|December 4, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysisJennifer R Brown, Javid Moslehi, Michael S Ewer, et al.
The Lancet. Haematology|December 24, 2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyRoger G Owen, Helen McCarthy, Simon Rule, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
Pageof 8